Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMR-687 extension study in adult sickle cell anemia
NCT04053803Phase 2Active, not recruiting
- Sponsor
- Imara Therapeutics
- Start
- May 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tovinontrine in sickle cell anemia (SCA), sponsored by Imara Therapeutics. Started May 2019; status: active, not recruiting.
02
Drugs
tovinontrine
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT04053803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053803.